ES2546847T3 - Formulaciones de un inhibidor de la Src/Abl - Google Patents

Formulaciones de un inhibidor de la Src/Abl Download PDF

Info

Publication number
ES2546847T3
ES2546847T3 ES06769997.5T ES06769997T ES2546847T3 ES 2546847 T3 ES2546847 T3 ES 2546847T3 ES 06769997 T ES06769997 T ES 06769997T ES 2546847 T3 ES2546847 T3 ES 2546847T3
Authority
ES
Spain
Prior art keywords
src
formulations
abl inhibitor
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06769997.5T
Other languages
English (en)
Inventor
Julia Zh Gao
Rajeshwar Motheram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Holdings Ireland ULC
Original Assignee
Bristol Myers Squibb Holdings Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37076246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2546847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland ULC filed Critical Bristol Myers Squibb Holdings Ireland ULC
Application granted granted Critical
Publication of ES2546847T3 publication Critical patent/ES2546847T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica para administración oral que comprende un vehículo farmacéuticamente aceptable y una cantidad terapéuticamente eficaz de un compuesto de fórmula (I), el solvato, el hidrato o la sal farmacéuticamente aceptable del mismo**Fórmula** y un recubrimiento no reactivo en donde el recubrimiento no reactivo es un recubrimiento que tiene polietilenglicol como plastificante.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES06769997.5T 2005-05-05 2006-05-04 Formulaciones de un inhibidor de la Src/Abl Active ES2546847T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67803005P 2005-05-05 2005-05-05
US678030P 2005-05-05
PCT/US2006/017073 WO2006121742A2 (en) 2005-05-05 2006-05-04 Formulations of a src/abl inhibitor

Publications (1)

Publication Number Publication Date
ES2546847T3 true ES2546847T3 (es) 2015-09-29

Family

ID=37076246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06769997.5T Active ES2546847T3 (es) 2005-05-05 2006-05-04 Formulaciones de un inhibidor de la Src/Abl

Country Status (18)

Country Link
US (2) US20060251723A1 (es)
EP (1) EP1885339B1 (es)
JP (1) JP5173794B2 (es)
CN (2) CN102813655A (es)
AR (1) AR054445A1 (es)
DK (1) DK1885339T3 (es)
ES (1) ES2546847T3 (es)
GE (1) GEP20104927B (es)
HR (1) HRP20151051T1 (es)
HU (1) HUE026040T2 (es)
NO (1) NO343939B1 (es)
PE (1) PE20061373A1 (es)
PL (1) PL1885339T3 (es)
PT (1) PT1885339E (es)
RS (1) RS54258B1 (es)
SI (1) SI1885339T1 (es)
TW (1) TWI386205B (es)
WO (1) WO2006121742A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3222619A1 (en) * 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
WO2006121742A2 (en) 2005-05-05 2006-11-16 Bristol-Myers Squibb Company Formulations of a src/abl inhibitor
EP1909795B1 (en) * 2005-06-09 2011-04-13 Bristol-Myers Squibb Company Pharmaceutical composition for use in treating individuals exhibiting mutant kit protein
US20070105867A1 (en) * 2005-09-21 2007-05-10 Bristol-Myers Squibb Company Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20090306094A1 (en) * 2006-03-17 2009-12-10 Bristol-Myers Squibb Company Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides
WO2008106059A1 (en) * 2007-02-26 2008-09-04 Merck & Co., Inc. Formulations for cathepsin k inhibitors
EP2359813A1 (en) 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
CN101891738B (zh) 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
JP5589097B2 (ja) * 2010-02-08 2014-09-10 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
CN104274420B (zh) * 2013-07-11 2019-03-05 石药集团中奇制药技术（石家庄）有限公司 一种达沙替尼组合物及其制备方法
WO2015107545A1 (en) 2013-12-18 2015-07-23 Dharmesh Mahendrabhai Shah Water soluble salts of dasatinib hydrate
WO2017144109A1 (en) 2016-02-25 2017-08-31 Remedica Ltd Dasatinib formulation
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
JP7249397B2 (ja) * 2017-12-27 2023-03-30 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020018053A2 (en) * 2018-05-25 2020-01-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi The tablet comprising dasatinib
JP7409696B2 (ja) 2018-06-15 2024-01-09 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物
GB2592680A (en) 2020-03-06 2021-09-08 Zentiva Ks Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
EP4071248A1 (en) 2021-04-07 2022-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Means and methods for enhancing receptor-targeted gene transfer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539380A (en) 1968-01-08 1970-11-10 Upjohn Co Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US5681382A (en) 1995-08-22 1997-10-28 Shin-Etsu Chemical Co., Ltd. Rapidly soluble coating composition and method for preparing same
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
EP3222619A1 (en) * 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CN1203852C (zh) * 1999-12-08 2005-06-01 法马西亚公司 维得克西组合物
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US20050215795A1 (en) 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2006121742A2 (en) 2005-05-05 2006-11-16 Bristol-Myers Squibb Company Formulations of a src/abl inhibitor

Also Published As

Publication number Publication date
JP5173794B2 (ja) 2013-04-03
US20130122093A1 (en) 2013-05-16
HUE026040T2 (en) 2016-05-30
EP1885339B1 (en) 2015-07-29
NO343939B1 (no) 2019-07-15
CN101170996A (zh) 2008-04-30
TW200716117A (en) 2007-05-01
SI1885339T1 (sl) 2015-10-30
EP1885339A2 (en) 2008-02-13
GEP20104927B (en) 2010-03-25
NO20075154L (no) 2008-02-01
JP2008540440A (ja) 2008-11-20
US20060251723A1 (en) 2006-11-09
DK1885339T3 (en) 2015-10-19
PE20061373A1 (es) 2006-12-15
CN102813655A (zh) 2012-12-12
WO2006121742A2 (en) 2006-11-16
AR054445A1 (es) 2007-06-27
PL1885339T3 (pl) 2015-12-31
TWI386205B (zh) 2013-02-21
WO2006121742A3 (en) 2007-02-22
RS54258B1 (en) 2016-02-29
PT1885339E (pt) 2015-10-12
HRP20151051T1 (hr) 2015-11-06

Similar Documents

Publication Publication Date Title
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
ES2525932T3 (es) Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
ES2551307T3 (es) Composición de inhalación que contiene aclidinio para tratamiento de enfermedad pulmonar obstructiva crónica
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
ES2545076T3 (es) Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
AR063098A1 (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
BRPI0719395B8 (pt) tablete revestido de filme
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
MA42946B1 (fr) Sels et formes solides d'un antibiotique de type monobactame
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
ECSP10010167A (es) Composiciones oftálmicas novedosas